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Background: Marketing authorization holders (MAHs) are obligated to report adverse events (AEs) within
15 days (some cases 30 days) to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
Methods: To analyze the timeliness of AE reporting to the PMDA, 6610 reports for ﬁve categories of cardiovascular
devices were retrieved. Two durations were calculated: (1) time from the date the AE occurred to that when the
MAH captured it (DOC: days); and (2) time from the date of MAH capture to that of MAH report (DCR: days).
Number of DOC N 15 days (DOC15) and delayed reports (DCR N 15 or 30 days) were also calculated.
Results: AEs included 9.2% deaths and 7.5% non-recoveries. DOC15 and delayed reports were 51.0% and 10.9%, re-
spectively. By multivariate analysis, DOC15 was associated with foreign AE, device category, MAH, patient out-
come, event category, and AE that had to be reported within 15 or 30 days (AE15/30). Delayed report was
associated with device category, MAH, patient outcome, event category, and AE15/30.
Comments: Although Japanese MAHs complied with the obligation to report AEs, they often failed to share AEs
with healthcare providers. Registrymay be a potential solution, although the cooperation of healthcare providers
to input data is essential.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).With the recent progress ofmedical technology, an increasing number
of new or modiﬁed medical devices that require special control has been
developed and approved for clinical use (List of approved products: new
& improved medical devices). The Pharmaceuticals and Medical Devices
Agency (PMDA) of Japan works on the principle that efﬁcacy and safety
must be adequately evaluated until approval is granted (Our
philosophy. Reviews and related services). However, it is also important
to balance this with patient access to such medical devices (Curfman
and Redberg, 2011). As the submission ﬁles for approval consist of a lim-
ited number of cases in pre-approval clinical trials, they are insufﬁcient to
reveal the entire safety proﬁle before approval. Adverse event (AE)
reporting is thus an important safety measure in combination with de-
tailed case investigation in a certain number of cases as a form of post-
marketing surveillance (PMS) in Japan (Post-marketing measures for
drug/medical devices; Kramer et al., 2013). Most AEs are provided by
the marketing authorization holder (MAH), while a very small number
of them come directly from healthcare professionals. Under the provisionict of interest to disclose.
Pharmaceuticals and Medical
F, Kasumigaseki, Chiyoda-ku,
da).
. This is an open access article underof the Japanese PMD ACT,1 article 68–10, Japanese MAHs are obligated to
report AEs of their own accord within either 15 or 30 days, depending on
the nature of the event (Fig. 1a) (Brief overview of the Draft Amendment
of Pharmaceutical Affairs Law (PAL)). It is crucial that such AEs be report-
ed promptly so that hazard signals can be detected immediately. The pur-
pose of the present study was to identify the factors that affect the
duration of time from AE occurrence to a PMDA report, and discuss how
to reduce such durations so that appropriate safety measures can be
taken in a timely manner.1. Materials and Methods
The present study was approved by the PMDA's review board and
was managed by the Department of Regulatory Science.
AEs that must be reported to the PMDA are separated into the
following ﬁve categories: AEs that result in death, AEs that are life
threatening, AEs that require inpatient hospitalization or prolongation
of existing hospitalization, AEs that result in persistent or signiﬁcant
disability or incapacity, and AEs that are a congenital anomaly or birth
defect.1 PMDACT: Act on SecuringQuality, Efﬁcacy and Safety of Pharmaceuticals, Medical De-
vices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Deﬁnition of DOC andDCR. DOC: duration from the datewhen AEoccurred to the datewhenMAH captured it. DCR: duration from the datewhenMAH capturedAE to the dateMAH
reported it. AE: adverse event, AE15: DCR of AEmust bewithin 15 days, AE15 consists of a death or any serious health damage that has not been listed in labeling, and any domestic death
event that has been already listed in labeling. AE30: DCR of AE must be within 30 days. AE30 consists of any serious health damage or foreign death event that is listed in labeling.
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cardiovascular devices that require surgical intervention were se-
lected for the current analysis because they are implanted perma-
nently, and because the failed products may require replacement
by re-do surgery. From the AE database at the PMDA, the initial re-
ports of AEs were retrieved from ﬁscal year 2004 through 2013. De-
tailed reports following the initial one were excluded from the
analysis, and a total of 6610 AE reports were identiﬁed. The ﬁve de-
vice categories consisted of bio-prosthetic heart valve, mechanical
heart valve, prosthetic vascular graft, stent graft, and valved conduit
for aortic root replacement.
There are two kinds of AE (Fig. 1). The ﬁrst type should be reported
to the PMDAwithin 15 days of MAH capture (AE15); whereas the other
type should be reported within 30 days (AE30) (Fig. 1). AE15s include
fatal events, any serious health damage not listed in the labeling, and
any domestic fatal event that has already been listed in the labeling.
AE30s consist of any serious health damage that has been listed in the
labeling or fatal foreign event that is listed in the labeling. Each AE
was classiﬁed into one of ﬁve event categories: device infection, device
related, patient related, procedure related, and under investigation at
the time of initial report. Two durations were calculated: duration
from the date when the AE occurred to the date when the MAH captured
it (DOC: days), and duration from the date when the MAH captured the
AE to the date when the MAH reported it to the PMDA (DCR: days)
(Fig. 1). Number of DOC15 (DOC N 15 days) and delayed reports
(DCR N 15 days in AE15 or DCR N 30 days in AE30) were also calculated.
This study was supported by internal funding from the PMDA.
1.1. Statistical Analysis
Statistical analysis was conducted using the statistical software
package JMP version 4.1 (SAS Institute, Inc.). The narrative paragraph
of each report was excluded, and the following seven variables, which
potentially affect DOC and DCR, were identiﬁed and utilized as explan-
atory variables: (1) location where the event occurred, either domestic
or foreign (LOC); (2) known or unknown event (KNW); (3) device cat-
egory; (4) JapaneseMAH; (5) event category; (6) patient outcome; and
(7) AE15/30. Two groups were compared using chi-square tests for
categorical variables and student t-test for continuous variables.
Comparison among multiple groups was conducted using a likeli-
hood ratio test for categorical variables and analysis of variance
(ANOVA) for continuous variables. Associations between DOC15Fig. 2. Number of AE reports over 10 years. AE: adverse event.and the seven variables, as well as between the variables and delayed
report, were analyzed by multiple logistic regression analysis. The
multivariate adjusted odds ratios (ORs) are expressed with 95% con-
ﬁdence intervals (CI). P values of less than 0.05 were considered sta-
tistically signiﬁcant.
2. Results
A total of 6610 AEswere reported over the 10-year period. The num-
ber of reports per year dramatically increased over the period (Fig. 2).
Median numbers of the two durations were 17 days (range: 0–6271)
in DOC, and 19 days (range: 0–1110) in DCR. Median of DOC and DCR
over the 10 years is shown in Fig. 3. Of the total AE reports, 51.0%
were DOC15, while 10.9% were delayed reports. Proportions of device
category, event category, patient outcome, LOC and KNW are listed in
the second left column of Table 1. The proportion of DOC15 and delayed
reports are detailed in the second column on the right side of Table 1. It
is noted that 94.1% of AEs were known events and 5.9% were unknown.
Japanese MAHs failed to capture 56.5% of unknown AEs within 15 days,
while 13.9% of unknown events had delayed reports. About half of AEs
occurred in foreign countries. Japanese MAHs failed to capture 74.7%
of AEs from foreign countries within 15 days, and 18.6% of AEs to the
PMDA were delayed.
Of the 6610 AE reports, about a quarter was AE15, while three quar-
ters were AE30. The proportion of DOC15 was higher in AE30 than in
AE15, while the proportion of delayed reports was higher in AE15Fig. 3.Medians of DOC and DCR over 10 years. DOC: duration from the date when adverse
event (AE) occurred to the date when marketing authorization holder captured it. DCR:
duration from the date when MAH captured AE to the date MAH reported it.
Table 1
Proportion of DOC15 and delayed report.
Proportion
(%)
DOC15 (%) P value Delayed
report (%)
P value
All AE reports 6610 (100%) 3305 (51.0%) 72 (10.9%)
Known or
unknown
Known event 6213 (94.1%) 315 (50.8%) 0.1189 67 (10.8%) 0.3555
Unknown
event
397 (5.9%) 224 (56.5%) 55 (13.9%)
Location of event
Domestic AE 3252 (49.2%) 741 (22.8%) b0.0001 16 (4.9%) 0.5316
Foreign AE 3358 (50.8%) 2508 (74.7%) 625 (18.6%)
AE15/30
Within 15 days 1752 (26.5%) 336 (19.2%) b0.0001 482 (27.5%) b0.0001
Within 30 days 4858 (73.5%) 3089 (63.6%) 209 (4.3%)
MAH
A 2132 (32.2%) 772 (36.2%) b0.0001 14 (0.66%) b0.0001
B 1477 (22.3%) 940 (63.6%) 570 (38.6%)
C 1223 (18.5%) 410 (33.5%) 58 (4.74%)
D 641 (9.7%) 335 (52.3%) 18 (2.81%)
E 595 (9.0%) 506 (85.0%) 25 (4.20%)
F 185 (2.8%) 120 (64.9%) 16 (8.65%)
G 152 (2.3%) 74 (48.7%) 7 (4.61%)
H 106 (1.6%) 23 (21.7%) 4 (3.77%)
Others 99 (1.5%) 59 (59.6%) 14 (14.1%)
Event category
Device
infection
336 (5.1%) 186 (55.4%) b0.0001 12 (3.6%) 0.0215
Device related 2932 (44.4%) 1358 (46.3%) 343 (11.7%)
Patient related 667 (10.1%) 446 (66.9%) 39 (5.8%)
Procedure
related
2193 (33.2%) 1097 (50.0%) 270 (12.3%)
Under
investigation
482 (7.3%) 305 (63.3%) 32 (6.6%)
Patient outcome
No health
damage
588 (8.9%) 255 (43.4%) b0.0001 91 (15.5%) b0.0001
Recovered 2571 (38.9%) 1327 (51.6%) 247 (9.6%)
Non-recovery 496 (7.5%) 192 (38.7%) 77 (15.5%)
Death 608 (9.2%) 424 (69.7%) 58 (9.5%)
Observation or
under
treatment
985 (14.9%) 171 (17.4%) 93 (9.4%)
Unknown or
under
investigation
1362 (20.6%) 801 (58.8%) 151 (11.1%)
Device category
Mechanical
heart valve
793 (12.0%) 416 (52.5%) b0.0001 29 (3.7%) 0.0350
Tissue heart
valve
945 (14.3%) 229 (24.2%) 45 (4.8%)
Prosthetic
vascular graft
304 (4.6%) 124 (40.8%) 32 (10.5%)
Stent graft 4383 (66.3%) 2533 (57.8%) 587 (13.4%)
Valved conduit 185 (2.8%) 62 (33.5%) 20 (10.8%)
Two groups were compared using chi-square tests for categorical variables and student t-
test for continuous variables. Comparison among multiple groups was conducted using a
likelihood ratio test for categorical variables and analysis of variance (ANOVA) for contin-
uous variables. DOC15: duration more than 15 days from the date the adverse event oc-
curred to that when the MAH captured it, AE: adverse event, AE15/30: adverse event
which should be reported within 15 days versus within 30 days, andMAH: marketing au-
thorization holder.
Fig. 4.DOC15/delayed report stratiﬁed by JapaneseMAH. DOC: duration from the date the
AE occurred to that when the MAH captured it and DOC15: DOC more than 15 days.
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were the most frequent, about 44.4% of AEs. AEs related to procedures
were the second most common. DOC15 of device-related AEs was
46.3%, while delayed report of device-related AEs was 11.7%. Fig. 4 is a
scatter diagram showing the proportions of DOC15 and delayed reports
stratiﬁed by Japanese MAH. The ﬁgure shows that out of eight major
MAHs in Japan, seven reportedmore than 90% of AEs to the PMDAwith-
in the legally determined duration. Meanwhile, the proportion of
DOC15 was widely varied among the MAHs. Among patient outcomes,
death and non-recovery events represented 9.2% and 7.5%, respectively.2.1. Multiple Logistic Regression Analysis for DOC15
Although the univariate analyses of the proportion of DOC15 for
KNW did not show any signiﬁcant differences (P = 0.1189), it can
potentially affect DCR. Therefore, all seven variables were included as
explanatory variables in the multiple logistic regression analysis of
DOC15. The result demonstrated that DOC15 was associated with the
seven explanatory variables as follows: LOC (P b 0.0001), KNW (P b
0.0001), device category (P b 0.0001), event category (P b 0.0001),
MAH (P b 0.0001), patient outcome (P b 0.0001), and AE15/30 (P b
0.0001) (Table 2). The multivariate adjusted odds ratio was calculated
with reference to the mechanical heart valve in the device category,
device-related AE in the event category, company A in MAH, and no
health damage in patient outcome. The results are shown in Table 2. Ad-
justed odds ratio of unknown to known AE regarding DOC15 was 3.35
(CI: 2.16–5.20, P b 0.0001). Adjusted odds ratio of foreign to domestic
AE was 8.72 (CI: 7.24–10.54, P b 0.0001). Several MAHs showed higher
odds ratio of DOC15 compared with company A. Out of the ﬁve event
categories, DOC15 of device infection had a signiﬁcantly higher odds
ratio compared to that of device-related events. In terms of patient out-
come, DOC15 of any AEs that caused any health damage to the patient
had a higher odds ratio than that of an AE that caused no heath damage.
In particular, DOC15 of a fatal event had the highest odds ratio of 5.84
(CI: 4.07–8.44).
2.2. Multiple Logistic Regression Analysis for Delayed Report
Although the univariate analyses of the proportion of delayed re-
ports for KNW and LOC did not show any signiﬁcant differences, they
potentially affect DCR. Therefore, all seven variables were included in
the multivariate analysis for delayed report. The results of multiple lo-
gistic regression analysis for delayed report demonstrated that it was
associated with device category (P = 0.0350), MAH (P b 0.0001), pa-
tient outcome (P b 0.0001), event category (P = 0.0215) and AE15/30
(P b 0.0001) (Table 3). The multivariate adjusted odds ratio was calcu-
lated in reference to the mechanical heart valve in the device category,
device-related AE in the event category, company A in MAH, and no
health damage in patient outcome. Delayed report was more frequent
in AE15 than in AE30. For certain MAHs, odds ratios of delayed report
were signiﬁcantly higher compared with that of company A. With re-
spect to event category, delayed report of procedure-related event
was less frequent than that of device-related AEs. In terms of patient
outcome, reports of health damage in which the patient either recov-
ered or did not recover were less frequent than events in which there
was no health damage.
Table 2
Results of multiple logistic regression analysis for DOC15.
Odds
ratio
95%
Lower
limit
95%
Upper
limit
P value P value
Known AE 1.00 Reference b0.0001
Unknown AEa 3.35 2.16 5.20
AE30 1.00 Reference b0.0001
AE15b 0.24 0.18 0.32
Domestic AE 1.00 Reference b0.0001
Foreign AEc 8.72 7.24 10.54
MHA
A 1.00 Reference b0.0001
B 1.96 1.53 2.55 b0.0001
C 3.48 2.71 4.48 b0.0001
D 0.66 0.41 1.04 0.0749
E 3.30 1.95 5.58 b0.0001
F 0.61 0.29 1.29 0.1971
G 1.37 0.75 2.48 0.3033
H 12.10 7.06 21.64 b0.0001
Others 1.38 0.70 2.65 0.3440
Event category
Device related 1.00 Reference b0.0001
Device infection 2.45 1.68 3.58 b0.0001
Patient related 1.27 0.96 1.67 0.0904
Procedure related 0.70 0.59 0.84 0.0001
Under investigation 1.13 0.85 1.51 0.3871
Patient outcome
No health damage 1.00 Reference b0.0001
Recovered 1.85 1.42 2.39 b0.0001
Unrecovered 2.03 1.45 2.84 b0.0001
Death 5.84 4.07 8.44 b0.0001
Observation or under
treatment
0.61 0.39 0.95 0.0303
Unknown or under
investigation
1.78 1.36 2.33 b0.0001
Device category
Mechanical heart valve 1.00 Reference b0.0001
Tissue heart valve 0.64 0.45 0.92 0.0152
Prosthetic vascular graft 2.61 0031.37 4.98 0.0038
Stent graft 1.85 1.14 2.99 0.0129
Valved conduit 0.65 0.37 1.12 0.1189
AE: adverse event. MAH: marketing authorization holder. DOC15: duration more than 15
days from the date the AE occurred to that when theMAH captured it. DCR: duration from
thedatewhen theMAHcaptured theAE to thedatewhen theMAH reported it to the Phar-
maceutical and Medical Device Agency. DCR of AE must be within 15 days, AE15 consists
of a death or any serious health damage that has not been listed in labeling, and any do-
mestic death event that has been already listed in labeling. AE30: DCR of AEmust be with-
in 30 days. AE30 consists of any serious health damage or foreign death event that is listed
in labeling.
Associations between DOC15 and the seven variables were analyzed by multiple logistic
regression analysis. The multivariate adjusted odds ratios (ORs) are expressed with 95%
conﬁdence interval (CI). P values of less than 0.05 are considered statistically signiﬁcant.
a The odds ratio of unknown AE refer to Known AE.
b The odds ration of AE15 refer to AE 30.
c The odds ration of foreign AE refer to domestic AE.
Table 3
Results of multiple logistic regression analysis for delayed report.
Odds
ratio
95%
Lower
limit
95%
Upper
limit
P value P value
Known AE 1.00 Reference 0.3555
Unknown AEa 1.34 0.72 2.43
AE30 1.00 Reference b0.0001
AE15b 3.51 2.26 5.50
Domestic AE 1.00 Reference 0.5316
Foreign AEc 0.87 0.57 1.34
MHA
A 1.00 Reference b0.0001
B 50.8 28.1 101.9 b0.0001
C 3.35 1.53 7.60 0.0025
D 1.87 0.64 5.55 0.2558
E 0.84 0.30 2.43 0.7415
F 0.38 0.43 12.39 0.3113
G 2.71 0.72 10.09 0.1405
H 5.57 1.20 19.17 0.0307
Others 5.22 11.47 18.14 0.0106
Classiﬁcation of event
Device related 1.00 Reference 0.0004
Device infection 0.83 0.34 1.77 0.6584
Patient related 1.11 0.62 1.90 0.725
Procedure related 0.66 0.52 0.85 0.0014
Under investigation 0.73 0.43 1.19 0.2148
Patient outcome
No health damage 1.00 Reference b0.0001
Recovered 0.44 0.30 0.66 b0.0001
Unrecovered 0.37 0.23 0.60 b0.0001
Death 0.71 0.42 1.21 0.2152
Observation or under
treatment
0.93 0.49 1.77 0.836
Unknown or under
investigation
0.86 0.57 1.30 0.4714
Device category
Mechanical heart valve 1.00 Reference b0.0001
Tissue heart valve 1.17 0.51 2.71 0.7184
Prosthetic vascular graft 2.28 0.65 7.66 0.194
Stent graft 0.56 0.23 1.45 0.2275
Valved conduit 1.73 0.68 4.45 0.251
AE: adverse event. MAH: marketing authorization holder. DCR: duration from the date
when theMAH captured the AE to the date when theMAH reported it to the Pharmaceu-
tical and Medical Device Agency. AE15: AE15 consists of a death or any serious health
damage that has not been listed in labeling, and any domestic death event that has been
already listed in labeling. AE30: DCR of AE must be within 30 days. AE30 consists of any
serious health damage or foreign death event that is listed in labeling.
Associations between the variables and delayed report were analyzed by multiple logistic
regression analysis. The multivariate adjusted odds ratios (ORs) are expressed with 95%
conﬁdence intervals (CI). P values of less than 0.05 are considered statistically signiﬁcant.
a The odds ratio of unknown AE refer to known AE.
b The odds ration of AE15 refer to AE 30.
c The odds ration of foreign AE refer to domestic AE.
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Out of the 6610 AEs, the PMDA took safety measures, such as recall,
for 44 events (0.67%) and modiﬁcation of package inserts for 51 events
(0.77%). More than half of AE reports (3940/6610) did not require any
additional safety measures, and 28.6% (1888/6610) only required re-
minders tomedical professionals of alerts or instructions for use already
noted in the package inserts.
3. Discussion
The PMDA was founded in April 2004. Since then, AE reports of
medical devices have been collected in the database of the PMDA
Safety Department. It was evident that the number of AEs increased
dramatically over the 10-year period considered here (Fig. 1b). This
must be related to the rapid increase in new and modiﬁed medicaldevices, in particular the approval of specially controlled medical de-
vices (List of approved products: new & improved medical devices).
In the present study, in order to analyze in how timely a manner the
PMDA has been provided with AE reports, two durations were calcu-
lated, DOC and DCR. DOC is related to how Japanese MAHs collect AE
reports from healthcare providers or the central headquarters of
manufacturers in foreign countries. Although healthcare profes-
sionals or medical institutions reported a very small number of AEs
directly to the PMDA, the overwhelming majority of AEs were re-
ported by Japanese MAHs (Kramer et al., 2013). In the details of the
study results, MAHs appeared to struggle to capture AEs character-
ized as unknown event, device infection, and certain types of pros-
theses such as prosthetic vascular graft or stent graft. In addition, it
took more than 15 days for MAHs to capture about 70% of fatal
events, and about 60% of events not listed in labeling or still under in-
vestigation at the time of the initial report. Unknown AEs and death
events should be reported to the PMDA immediately so that the hid-
den health hazard can be determined. Overall, only 49% of AEs were
recognized by MAHs within 15 days. Although most MAHs reported
1215N. Handa et al. / EBioMedicine 2 (2015) 1211–1216more than 90% of AEs within the legally determined duration, the
proportion of DOC15 varied widely among Japanese MAHs (Fig. 2).
This was probably due to varying attitudes of MAHs as to how ag-
gressively to collect AEs, or to the philosophy of foreign manufac-
turers as to how to share AEs with Japanese MAHs.
The Japanese Pharmaceutical Affairs Law was amended to the PMD
ACT in November 2013, which enforces the safety of drugs, medical de-
vices and regenerative products (Act on Securing Quality, Efﬁcacy and
Safety of Pharmaceuticals, Medical Devices, Regenerative and Cellular
Therapy Products, Gene Therapy Products, and Cosmetic). The
Japanese PMD ACT imposes AE reports and PMS, as well as clinical
evaluation and inspection on MAHs that sell Class III or IV devices. It
mandated that Japanese MAHs report AEs directly to the PMDA (Article
68–10) (Kramer et al., 2013). Regarding foreign AEs, Japanese MAHs
have a strict obligation to obtain such information from themanufactur-
er or medical healthcare professionals abroad and report them to the
PMDA immediately. Unfortunately, the present study suggested that
AEs from foreign countrieswere signiﬁcantly delayed, probably because
foreign manufacturers failed to share AEs with healthcare providers, or
because these manufacturers delayed informing the Japanese MAHs
about the AE. Healthcare providers and foreign manufacturers are
asked to make an effort to cooperate with Japanese MAHs. After the
PMDA analyzes an individual AE report, it may conclude that further ac-
tion is required, and impose additional safety measures such as recalls
or changes in labeling. Although AEs that required additional measures
totaled only 1.4% in this study, timely reporting of AEs is fundamental to
the success of PMS. As a safetymeasure, the Japanese PMDACT requires
MAHs to provide the most recent evidence regarding the effectiveness
and safety proﬁle in the package inserts of drugs, medical devices, and
regenerative products (Brief overview of the Draft Amendment of
Pharmaceutical Affairs Law (PAL)). The modiﬁcation and new evidence
must then be registered in the PMDAdatabase and disclosed to the pub-
lic (Act on Securing Quality, Efﬁcacy and Safety of Pharmaceuticals,
Medical Devices, Regenerative and Cellular Therapy Products, Gene
Therapy Products, and Cosmetic).
The efﬁcacy and safety proﬁle of new drugs and devices should be
reasonably demonstrated in the pre-market review process before ap-
proval. However, the limited number of cases in the submission ﬁle,
limited combination therapy, and limited follow-upperiod leaves unan-
swered questions of effectiveness and safety. The PMS in Japan includes
systems for reporting foreign and domestic AEs, identifying safety sig-
nals emerging from international markets, and re-ﬁling applications
3–7 years after initial market approval (Kramer et al., 2013; Brief
overview of the Draft Amendment of Pharmaceutical Affairs Law
(PAL)). Japan has a unique system to reexamine approved devices
that carry a high risk by surveying all cases in a pre-speciﬁed period
or pre-determined number of subjects. Sponsors must aggregate infor-
mation from healthcare providers, clinical trials, and published studies
such as foreign and domestic observational research or experience
from registries to demonstrate that the device is providing the expected
safety and effectiveness results (Kramer et al., 2013; Brief overview of
the Draft Amendment of Pharmaceutical Affairs Law (PAL)). Although
a brief report is submitted to the PMDA annually, a ﬁnal report to re-
ﬁle that includes full assessment of effectiveness and safety is usually
submitted 3–7 years after approval. By then, a modiﬁed device may
have been approved so that that the original device may have disap-
peared from the market. It is obvious that life-cycle management of
medical devices has shortened due to frequent modiﬁcations in re-
sponse to requests from the clinical ﬁeld (Act on Securing Quality,
Efﬁcacy and Safety of Pharmaceuticals, Medical Devices, Regenerative
and Cellular Therapy Products, Gene Therapy Products, and Cosmetic;
Levesque et al., 2014). Early detection of new hazards is essential in
the short life cycle of device modiﬁcation. In addition, if the modiﬁca-
tion of the device is small, leaving themodiﬁed device practically equiv-
alent to the original one, no clinical data or re-assessment is necessary
for approval. In such cases, AE reports are the only source of informationin detecting hidden hazard signals. Accordingly, AE reports play a cen-
tral role in detecting hazard signals quickly after approval.
The PMDA address two conﬂicting goals: the ﬁrst is to assure the
public that the devices are reasonably safe and effective; and the second
is to avoid overregulation of manufacturers in the development of Class
III or IV devices (Post-marketing measures for drug/medical devices).
The PMDA shifted the regulatory standards to a less burdensome ap-
proach in all areas of medical devices and reduced the terms of device
development. As a part of the implementation of reducing such terms
for certain devices with little clinical data in the Japanese population,
the PMDA has accepted clinical trials conducted in the US, European
Union, or other countries. In these cases, reports of foreign aswell as do-
mestic AEs are an extremely important source of information.
Registry, in collaboration with academic societies as well as manu-
facturers, is a promising potential solution for PMS (Resnic and
Normand, 2012). For example, Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) was very successful in
monitoring the results of a left ventricular assist device in the real
world and detecting hazard signals (Grady et al., 2015 Feb; Kirklin
et al., 2014). J-MACS, the Japanese version of INTERMACS, has a system
that sends an alert mail to the device companywhen healthcare profes-
sionals input an AE into the system (Japanese Registry for Mechanically
Assisted Circulatory Support). AEs in combination with registry of
follow-up data would provide both the number of events and number
of devices implanted for a patient-year follow-up period. One possible
drawback of registry is that the more patients that register with the de-
vice, themore difﬁcult itwould be to collect follow-up data (Smith et al.,
2012). However, in the advent of trans-catheter aortic valve replace-
ment (TAVR) in Japan, PMSwith anAE alertmail systemwas embedded
in a national TAVR registry formed by academic societies; and the sys-
tem is designed to collect 5 years of follow-up data (Japanese Registry
of Trans-Catheter Aortic Valve Replacement).
4. Conclusions
The present study suggested that multiple factors inﬂuenced the
delay of AE reports. Japanese MAHs had difﬁculty in sharing AE appro-
priately with healthcare providers or foreign manufacturers, particular-
ly for critical events such as death or unknown event. Registry, in
combination with a system to alert the MAH, may be a potential solu-
tion for functional AE reporting. Even so, the cooperation of healthcare
providers to input the data into the registry will be essential. Once a
medical device is approved for the Japanese market, it is strongly en-
couraged thatMAHs develop a functional AE reporting system in collab-
oration with healthcare providers and academic societies, particularly
given the current short life cycle of new or modiﬁed medical devices.
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